Compare Hyatt Hotels Corporation (H) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Tango Therapeutics Inc. — how do they compare? Hyatt Hotels Corporation trades at $160.32 (market cap $15.11B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: Hyatt Hotels Corporation is far larger — about 4× Tango Therapeutics Inc.'s market cap, and Hyatt Hotels Corporation pays a 0.37% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 149 Days and Tango Therapeutics Inc. for 0 Days on average.
| H | TNGX | |
|---|---|---|
Market Cap | $15.11B | $3.74B |
Volume | 769,803 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $32.90 |
52-Week Low | $135.42 | $7.50 |
Typical Hold Time | 149 Days | 0 Days |
Enterprise Value | $19.01B | $2.76B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $162.92, up 1.08% on the day, with a bullish technical signal and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. The stock is supported by a consensus price target of $197.92, representing a 21% upside, and positive news including a strategic loyalty collaboration with Delta Air Lines and portfolio expansion. However, valuation metrics like a P/E of 197.93 and a net income margin of 1.1% indicate premium pricing relative to modest profitability.
The outlook for H is cautiously optimistic, driven by earnings momentum and strategic initiatives, but high valuation and fluctuating cash flows pose risks. Investors should weigh the potential for continued operational growth against the stock's rich multiples and macroeconomic sensitivity in the hospitality sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
